{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:27:44Z","timestamp":1725668864828},"reference-count":42,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14584","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T11:55:50Z","timestamp":1721735750000},"source":"Crossref","is-referenced-by-count":0,"title":["Newer combination treatments for breast cancer coexisting with acute myeloid leukemia in the novel regimens era: A case report and literature review"],"prefix":"10.3892","volume":"28","author":[{"given":"Lina","family":"Xing","sequence":"first","affiliation":[{"name":"Department of Hematology, Hebei Key Laboratory of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hebei Key Laboratory of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hebei Key Laboratory of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingnan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hebei Key Laboratory of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hebei Key Laboratory of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shukai","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hebei Key Laboratory of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"key20240906090728_b1-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3349\/ymj.2015.56.5.1213","article-title":"Characteristics and survival of breast cancer patients with multiple synchronous or metachronous primary cancers","volume":"56","author":"Lee","year":"2015","journal-title":"Yonsei Med J"},{"key":"key20240906090728_b2-ol-28-4-14584","first-page":"458","article-title":"Acute myeloblastic leukemia in an 84-year-old woman, associated with a breast cancer and a mixed parotid tumor without metastasis","volume":"4","author":"Softic","year":"1964","journal-title":"Nouv Rev Fr Hematol"},{"key":"key20240906090728_b3-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/1097-0142(196707)20:7<1080::AID-CNCR2820200711>3.0.CO;2-O","article-title":"Association of cancer of the breast and acute myelocytic leukemia","volume":"20","author":"Carey","year":"1967","journal-title":"Cancer"},{"key":"key20240906090728_b4-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/ajh.2830040207","article-title":"Breast cancer and acute leukemia: Report of 24 cases and review of the literature","volume":"4","author":"Rosner","year":"1978","journal-title":"Am J Hematol"},{"key":"key20240906090728_b5-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00000441-198209000-00004","article-title":"Emergence of acute non-lymphocytic leukemia in breast cancer patients","volume":"284","author":"Ershler","year":"1982","journal-title":"Am J Med Sci"},{"key":"key20240906090728_b6-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-004-0852-0","article-title":"Synchronous occurrence of breast carcinoma and acute myeloid leukemia: Case report and review of the literature","volume":"83","author":"Mishra","year":"2004","journal-title":"Ann Hematol"},{"key":"key20240906090728_b7-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000443494","article-title":"Appropriate clinical strategies for breast cancer coexisting with acute myeloid leukemia in the genomic-molecular era: A case report","volume":"11","author":"Hu","year":"2016","journal-title":"Breast Care (Basel)"},{"key":"key20240906090728_b8-ol-28-4-14584","first-page":"8893185","article-title":"A rare case of coexisting breast cancer and refractory acute myeloid leukemia","volume":"2020","author":"Ballotta","year":"2020","journal-title":"Case Rep Hematol"},{"key":"key20240906090728_b9-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0268-960X(03)00036-5","article-title":"The therapy of relapsed acute leukaemia in adults","volume":"18","author":"Litzow","year":"2004","journal-title":"Blood Rev"},{"key":"key20240906090728_b10-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3390\/cells9051287","article-title":"Inhibition of anti-apoptotic Bcl-2 proteins in preclinical and clinical studies: Current overview in cancer","volume":"9","author":"D'Aguanno","year":"2020","journal-title":"Cells"},{"key":"key20240906090728_b11-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/bs.acr.2017.11.001","article-title":"Bcl-2 antiapoptotic family proteins and chemoresistance in cancer","volume":"137","author":"Maji","year":"2018","journal-title":"Adv Cancer Res"},{"key":"key20240906090728_b12-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL-2 and MCL-1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"key":"key20240906090728_b13-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"key20240906090728_b14-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"13357","DOI":"10.2147\/OTT.S281519","article-title":"BCL-2 inhibivtor venetoclax induces autophagy-associated cell death, cell cycle arrest, and apoptosis in human breast cancer cells","volume":"13","author":"Alhoshani","year":"2020","journal-title":"Onco Targets Ther"},{"key":"key20240906090728_b15-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"key20240906090728_b16-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 Years of image analysis","volume":"9","author":"Caroline","year":"2012","journal-title":"Nat Methods"},{"key":"key20240906090728_b17-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/iep.12185","article-title":"Protocol for HER2 FISH determination on PAXgene-fixed and paraffin-embedded tissue in breast cancer","volume":"97","author":"Oberauner-Wappis","year":"2016","journal-title":"Int J Exp Pathol"},{"key":"key20240906090728_b18-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3322\/caac.21393","article-title":"Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Giuliano","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"key20240906090728_b19-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.03.015","article-title":"Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort","volume":"96","author":"Gobbini","year":"2018","journal-title":"Eur J Cancer"},{"key":"key20240906090728_b20-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortbagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"key20240906090728_b21-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","article-title":"Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer","volume":"28","author":"Di Leo","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20240906090728_b22-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/1758834015608993","article-title":"Optimal management of hormone receptor positive metastatic breast cancer in 2016","volume":"7","author":"Reinert","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"key20240906090728_b23-ol-28-4-14584","first-page":"2821","article-title":"ER+ metastatic breast cancer: Past, present, and a prescription for an apoptosis-targeted future","volume":"9","author":"Rozeboom","year":"2019","journal-title":"Am J Cancer Res"},{"key":"key20240906090728_b24-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.3390\/ijms21186479","article-title":"Targeting cell cycle in breast cancer: CDK4\/6 inhibitors","volume":"21","author":"Piezzo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20240906090728_b25-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1080\/14656566.2023.2214677","article-title":"Evaluating everolimus for the treatment of breast cancer","volume":"24","author":"Moreau-Bachelard","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"key20240906090728_b26-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2021.08.592","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Final overall survival results from SOLAR 1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann Oncol"},{"key":"key20240906090728_b27-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/2159-8290.CD-18-1151","article-title":"A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer","volume":"9","author":"Lok","year":"2019","journal-title":"Cancer Discov"},{"key":"key20240906090728_b28-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.3390\/jcm10215096","article-title":"BCL-2 expression in AML patients over 65 years: Impact on outcomes across different therapeutic strategies","volume":"10","author":"Tiribelli","year":"2021","journal-title":"J Clin Med"},{"key":"key20240906090728_b29-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"key":"key20240906090728_b30-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"key":"key20240906090728_b31-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20240906090728_b32-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"key20240906090728_b33-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","article-title":"Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: Evaluation of the proposed reporting system","volume":"29","author":"R\u00f6llig","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20240906090728_b34-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"key20240906090728_b35-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/j.seminoncol.2008.04.007","article-title":"Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype","volume":"35","author":"Mr\u00f3zek","year":"2008","journal-title":"Semin Oncol"},{"key":"key20240906090728_b36-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","article-title":"Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype","volume":"26","author":"Breems","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20240906090728_b37-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/10428194.2016.1219901","article-title":"Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype-retrospective analysis of Polish adult leukemia group (PALG)","volume":"58","author":"Wierzbowska","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"key20240906090728_b38-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/ajh.25214","article-title":"Acute myeloid leukemia: 2019 Update on risk-stratification and management","volume":"93","author":"Estey","year":"2018","journal-title":"Am J Hematol"},{"key":"key20240906090728_b39-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11864-019-0612-y","article-title":"Prognostic significance of complex karyotypes in acute myeloid leukemia","volume":"20","author":"Daneshbod","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"key20240906090728_b40-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3390\/cells10071659","article-title":"ER+ breast cancer strongly depends on MCL-1 and BCL-xL anti-apoptotic proteins","volume":"10","author":"Alcon","year":"2021","journal-title":"Cells"},{"key":"key20240906090728_b41-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ccr.2013.06.002","article-title":"Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer","volume":"24","author":"Vaillant","year":"2013","journal-title":"Cancer Cell"},{"key":"key20240906090728_b42-ol-28-4-14584","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1158\/1078-0432.CCR-21-3811","article-title":"VERONICA: Randomized phase II study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4\/6 inhibitors-efficacy, safety, and biomarker results","volume":"28","author":"Lindeman","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T06:07:33Z","timestamp":1725602853000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,7,23]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14584","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"article-number":"451"}}